Randall Rosenblatt, MD
Pulmonary Disease · Dallas, TXNPI 1871531004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by GSK at 49.8% of the total. Reporting peaked in 2019 at $222 and has fallen 60.5% since, to $88 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 28 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$280
- Insmed, Inc.$51
- E.r. Squibb & Sons, L.L.C.$34
- Sanofi$32
- Lexicon Pharmaceuticals, Inc.$31
- Shionogi Inc$29
- plus $105 from 5 others
Across 108 payments — averaging $1083.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$79K
- Paratek Pharmaceuticals, Inc.$38K
What the payments were for
- Food & beverage$54196%
- Education$214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $280 |
| Insmed, Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 1 | $34 |
| Sanofi | 1 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $31 |
| Shionogi Inc | 1 | $29 |
| Medtronic | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Chiesi USA, Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $17 |
| AstraZeneca | 1 | $14 |
How this compares
$563 in reported general payments places this provider in the 30th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 86 | $2,242,389 |
| OfevNintedanib Esylate | 83 | $1,053,494 |
| Ambrisentan | 14 | $106,935 |
| ZenpepLipase/Protease/Amylase | 16 | $94,573 |
| Dupixent SyringeDupilumab | 13 | $57,277 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $41,489 |
| EliquisApixaban | 51 | $25,516 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $23,362 |
| Valganciclovir Hcl | 55 | $13,521 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $11,807 |
| Atovaquone | 20 | $11,598 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $4,557 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,237 |
| Azithromycin | 145 | $4,046 |
| Sirolimus | 20 | $3,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $280 | $76,659107 claims |
| AstraZenecaSymbicort | $14 | $4,23716 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $26 | $18213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.